<DOC>
	<DOC>NCT01493622</DOC>
	<brief_summary>The purpose of this study is to determine whether minocycline are effective in the treatment of negative and cognitive symptoms in schizophrenia.</brief_summary>
	<brief_title>The Study of Minocycline for Negative and Cognitive Symptoms in Schizophrenia</brief_title>
	<detailed_description>Immune-related disorders have been hypothesized as etiological factors in schizophrenia.Minocycline is a second-generation tetracycline that exerts anti-inflammatory and antimicrobial effects while having a distinct neuroprotective profile.This study was performed as a double-blind, placebocontrolled,randomized evaluation of Second generation antipsychotics(SGA) and minocycline versus SGA and placebo.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Neurobehavioral Manifestations</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>male and female,were aged 1840 years were currently diagnosed with DSMIV schizophrenia were able to comprehend the cognition test patients or guardian signed informed consent,were able to comprehend the procedure and aims of the study,agreed to join the study patient's current antipsychotic medication regimen must be stable must be in a stable living arrangement had ever been hypersensitivity to minocycline or tetracycline; had acute,unstable,significant,or untreated medical illness besides schizophrenia were pregnant or breastfeeding; had a DSMIV diagnosis of substance abuse or dependency; had a tendency to suicide or Violence,selfharm; had taken immunosuppressive agents in the preceding 3 months before study entry; had influenza or fever in the preceding 2 weeks before study entry; had a DSMIV diagnosis of emotional psychosis,Mental retardation,etc. has suicidal attempts or ideation or violent behavior within the last 12 months patient has mental retardation or severe organic brain syndromes treatment with Electroconvulsive Therapy (ECT) within 6 months prior to screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Schizophrenia minocycline cognition</keyword>
</DOC>